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Antracyclines are effective antitumor agents. One of the most commonly used antracyclines is doxorubicin, which can be
successfully used to treat a diverse spectrum of tumors. Application of these drugs is limited by their cardiotoxic effect, which
is determined by a lifetime cumulative dose. We set out to identify by high throughput screening cardioprotective compounds
protecting cardiomyocytes from doxorubicin-induced injury. Ten thousand compounds of ChemBridge’s DIVERSet compound
library were screened to identify compounds that can protect H9C2 rat cardiomyocytes against doxorubicin-induced cell death.
The most effective compound proved protective in doxorubicin-treated primary rat cardiomyocytes and was further characterized
to demonstrate that it significantly decreased doxorubicin-induced apoptotic and necrotic cell death and inhibited doxorubicin-
induced activation of JNK MAP kinase without having considerable radical scavenging effect or interfering with the antitumor
effect of doxorubicin. In fact the compound identified as 3-[2-(4-ethylphenyl)-2-oxoethyl]-1,2-dimethyl-1H-3,1-benzimidazol-3-
ium bromide was toxic to all tumor cell lines tested even without doxorubicine treatment.This benzimidazole compoundmay lead,
through further optimalization, to the development of a drug candidate protecting the heart from doxorubicin-induced injury.
1. Introduction
Doxorubicin (DOX) is an anthracycline compound originally
isolated from bacteria of the Streptomyces genus and used
extensively for the treatment of various types of cancer [1–
3]. Acute leukemias, Hodgkin and non-Hodgkin lymphomas,
osteosarcoma, Ewing sarcoma, breast cancer, neuroblastoma,
and small cell lung cancer respondwell toDOXmonotherapy
or combination therapy [4, 5]. Even though doxorubicin and
other anthracycline compounds such as daunorubicin have
been used by oncologists for more than four decades, their
mechanism of action is still not fully understood [6]. Inhi-
bition of topoisomerase II𝛽, generation of reactive oxygen
species, DNA intercalation and triggering a signaling cascade
that involves increased ceramide production, cleavage of the
ER membrane protein CREB3L1, nuclear translocation of
the N-terminal fragment of this protein, and transcriptional
activation of genes that inhibit cell proliferation have been
suggested to be responsible for the antitumor effect of
anthracyclins [6–8].
The clinical use of DOX is limited mainly by its severe
cardiotoxic effect, which may lead to irreversible cardiomy-
opathy and heart failure [9]. Incidence of heart failure shows
close correlation with the cumulative dose of the drug so that
it is suggested not to exceed 550mg/m2 [10, 11].
Cardiotoxicity is indicated by morphological alterations
(myofibrillar disarray and vacuolization) as observed in
cardiac biopsy specimens. Moreover, leakage of troponin can
also be detected in the peripheral blood and shows positive
correlation with the intensity of heart damage [12, 13]. The
mechanism of doxorubicin cardiotoxicity is complex and
is closely linked to production of reactive oxygen species.
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These form indirect electron exchange between the oxy-
gen molecule and the anthracyclines’ quinone moiety and
can also be produced in redox cycling of doxorubicin-iron
complexes [14–16]. Superoxide, hydrogen peroxide, hydroxyl
radical, and peroxynitrite have all been implicated in DOX-
induced cardiac injury [17, 18]. The role of redox stress is
also supported by observations that oxidative stress-induced
signaling pathways (e.g., p38 MAP kinases, poly(ADP-
ribose) polymerase-1, matrix metalloproteinases, etc.) and
metabolic alterations also contribute to the cardiotoxic effects
of DOX [19–22]. Moreover, a series of animal experiments
has also demonstrated the effectiveness of a ferroporphyrin
antioxidant [18], a vitamin E prodrug [23], or a poly(ADP-
ribose) polymerase (PARP) inhibitor [24] in preventing or
suppressing the cardiotoxic effect of DOX. In recent years
topoisomerase 2𝛼 has emerged as a central mediator of
DOX-induced cardiac injury [25]. While topoisomerase 2𝛽
(expressed mostly in proliferating cells) is considered as the
primary target of DOX in tumor cells, topoisomerase 2𝛼
(expressed by quiescent cells) has been made responsible for
suppression of antioxidant enzyme expression, inhibition of
mitochondrial biogenesis, and activation of p53 and p53-
mediated apoptosis with all of these cellular events implicated
in DOX-induced heart failure [25].
Despite our increasing knowledge on the mechanism of
DOX-induced heart injury, it still represents an unsolved
medical problem necessitating more mechanistic studies as
well as the development of novel agents for the prevention of
the side effect of anthracyclins. Here we report a screening
strategy for the identification of potentially cardioprotec-
tive compounds with the capacity to prevent DOX-induced
cardiomyocyte injury. With this HTS approach we iden-
tified 3-[2-(4-ethylphenyl)-2-oxoethyl]-1,2-dimethyl-1H-3,1-
benzimidazol-3-ium bromide (EODB) as a novel compound
protecting cardiomyocytes fromDOX-induced damagewith-
out interfering with its tumor killing activity.
2. Materials and Methods
2.1. Materials. Dimethyl-sulfoxide, ABTS (A1888), DMEM
medium (Gibco 41966), copper(II) chloride dihydrate
(307483), neocuproine (N1501), calcein-AM (17783), sulfor-
hodamine B (230162), horseradish peroxidase (P8375),
xanthine (X4002), xanthine oxidase (X4500), nitroblue
tetrazolium (NBT) (N6876), superoxide dismutase (S7571),
and Ampliflu Red (90101) were purchased from Sigma-
Aldrich (Saint Louis, MO, USA). RPMI 1640 cell culture
medium (BE12-115F), glutamine (BE17-605F), and fetal
bovine serum (DE14-802F) were purchased from Lonza
(Basel, Switzerland). DIVERset 10 000 compound library
was purchased from ChemBridge (San Diego, CA, USA).
Doxorubicinwas purchased fromTeva (Debrecen,Hungary).
2.2. Cell Culture
2.2.1. Cell Lines. H9C2 cells were cultured in DMEM (10%
FBS and 2mM glutamine, 5 g/L glucose). A549, Jurkat,
and THP-1 cell lines were cultured in RPMI 1640 medium
supplemented with 10% FBS and 2mM glutamine. SAOS-
2 cell line was cultured in DMEM (10% FBS and 2mM
glutamine, 1 g/L glucose).
2.2.2. Primary Neonatal Rat Cardiomyocyte Culture. Primary
neonatal cardiomyocyte culture was prepared from 1–3-day-
old Wistar rats as described earlier [26, 27]. Pups were
killed by cervical dislocation, and then the hearts were
harvested and rinsed in ice-cold PBS buffer. The ventri-
cles were then chopped and digested in 0.25% trypsin for
25min. To increase the number of cardiomyoblasts in the
cell suspension, 90min preplating was applied in 10% FBS-
containingDMEM.Then cells were plated at 1.5× 104 cell/well
density in 96-well plates with 10% FBS-containing DMEM
supplemented with 1% glutamine and antibiotic/antimycotic
solution. Cells were maintained in a humidified incubator
(37∘C, 5% CO
2
). After 24 hours, the medium was changed to
DMEM containing 1% FBS to help cardiomyoblast differenti-
ation.
2.3. MTT Viability Assay. For the HTS screening H9C2 cells
(7 × 103/well) were plated to 96-well plates one day before
the treatment. Compounds of the library were transferred
to the plates with a Tecan Freedom EVO liquid handling
robot (100 nL/well) to reach 10 𝜇M final concentration. Each
compound was tested on two separate microplates. (Controls
received the corresponding concentration of the vehicle
DMSO). After 30min incubation at 37∘C, cells were treated
with doxorubicin (final concentration: 300 ng/mL) or cell
culture medium (control). Samples were incubated for 24
hours at 37∘C. 10 𝜇L MTT solution (5mg/mL) was added
to the samples (final concentration: 0.5mg/mL). Samples
were incubated for 120min, at 37∘C. Supernatants were
aspirated and replaced by DMSO (50 𝜇L/well). Measurement
was performed with a Thermo Multiskan reader at 540 nm.
Viability data were expressed as the percentage of control.
Compounds with more than 20% efficiency were regarded as
cardioprotective.
The non-HTS (manual) version of the assay was carried
out the sameway except for the fact that test compoundswere
given to the cells with manual pipettes. The assay protocol
differed for nonadherent cell lines (Jurkat and THP-1). In this
case, cells (105/well) were seeded into 96-well plates and were
treated with EODB and DOX as described above. 24 h after
DOX treatment, cells were transferred to V-bottom plates.
MTTwas added, and cells were incubated as described above.
Plates were then spun down (1600 rpm, 5min), medium
was aspirated, and DMSO (75𝜇L) was added to dissolve
the cells and the formazan crystals. Fifty microliter aliquots
were transferred to flat bottom plates for determination of
absorbance as described above.
2.4. Cytotoxicity Assay Based on Cell-Covered Area. H9C2
cells (7 × 103/well) were seeded into 96-well plates one
day before the treatment. Cells were treated with the hit
compounds of the screening, in the final concentration of
12 𝜇M. (Controls received the corresponding concentration
of the vehicle DMSO). After 30min incubation at 37∘C,
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cells were treated with doxorubicin (300 ng/mL final con-
centration) or cell culture medium (control). Samples were
incubated for 24 hours at 37∘C. Cell culture medium was
changed toCoomassie staining solution (0.1%) and incubated
for 20 minutes. Samples were washed once with PBS and
dried. From each condition altogether nine images were
taken (3 wells from 3 independent experiments) with a Leica
SP8 microscope and were used for the calculation of cell-
covered area in each condition. Image analysis performed
with Tscratch software was used to determine the size of cell-
covered areas.
2.5. Calcein-Based Viability Assay. Cell viability of H9C2
cells (7 × 103/well) and two-day-old primary rat neonatal
cardiomyocytes (1.5 × 104 cell/well) was also determined with
the calcein-AM assay. Cells were pretreated with 12𝜇M (for
H9C2 cells) or 5–25𝜇M (for primary cells) of compound#10
or its vehicle (DMSO) for 30 minutes followed by 300 ng/mL
doxorubicin treatment for 24 hr. Compound#10 treatments
were maintained during the doxorubicin challenge. At the
end of the protocol, viability was determined by calcein-AM
assay [28]. After washing twice with D-PBS, primary car-
diomyocytes were incubated with 1 𝜇M calcein AM (Sigma,
Saint Louis, MO) for 30min at room temperature. In liv-
ing cells, the cell-permeable calcein AM (nonfluorescent)
is hydrolyzed by intracellular esterases to calcein (green-
fluorescent). Fluorescence intensitywasmeasured following a
washing step bymeans of a fluorescence plate reader (Fluostar
Optima, BMG Labtech, Ortenberg, Germany) using 490-nm
excitation and 520-nm emission filters.
2.6. Visualization of Cellular Morphology. For the concen-
tration finding experiment and for illustrating alterations
in the morphology and number of cells following DOX
treatment, we stained cell cultures (H9C2 in concentration
finding experiments; A549 and SAOS-2 cells in the antitumor
experiments) with the Coomassie dye as described under
Section 2.4.
2.7. Caspase-3 Activity Measurement. Measurement of cas-
pase activity (from both H9C2 (3 × 104/well) and primary
cardiomyocyte cultures (5 × 104 well)) was performed as
described before [29].
2.8. Combined Measurement of Viability and Necrotic Cell
Death. Survival and necrotic death of H9C2 cells (7 ×
103/well) has been determined by sequential measurement of
the activity of lactate dehydrogenase (LDH) released by the
cells into the culture supernatants (as described before [30])
followed by determination of cell viability using the calcein-
AM assay as described above.
2.9. Measurement of Cell Proliferation. Cell proliferation was
determined with the sulforhodamine B (SRB) assay [31]. The
assay is based on the ability of the protein dye sulforhodamine
B to bind electrostatically and in a pH dependent manner to
basic amino acid residues of proteins in trichloroacetic acid-
(TCA-) fixed cells. Undermild acidic conditions SRB binds to
the cells and under mild basic conditions it can be extracted
and solubilized for measurement. Cells were seeded into 24-
well plates at a density of 2.5 × 103 and treated with 12.5 𝜇M
EODB and 300 nM DOX alone or in combination for 5 days.
(Controls received the same amount of DMSO vehicle as the
EODB samples.) Cells were then fixed with 10% TCA for 1
hour at 4∘C, washed 5 times with distilled water and air dried.
Cells were stained with 0.4% (w/v) sulforhodamine B (SRB)
solution in 1% acetic acid for 10 minutes. Unbound dye was
removed by washing 5 times with 1% acetic acid and plates
were air dried. Bound stain was solubilised with 10mM Tris
base and absorbance was read at 540 nm using a Multiskan
MS plate reader (Labsystems, Vantaa, Finland). Proliferation
capacity is expressed as percentage of vehicle control.
2.10. Measurement of Free Radical Scavenging with the ABTS
Decolorization Assay. Measurement of the radical scaveng-
ing activity of EODB was performed as described before
[32] with slight modifications as follows. ABTS decoloriza-
tion assay utilizes a chromogenic free radical, the radi-
cal monocation of 2,2󸀠-azinobis-(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS∙+), which is decolorized during reduc-
tion by hydrophilic or lipophilic antioxidants. ABTS∙+ radical
cation was generated by oxidation of ABTS with potassium
persulfate overnight one day before the experiment. ABTS
was dissolved in water to a 7mM concentration and this
stock solution was allowed to react with potassium persulfate
(2.45mM final concentration) followed by incubation in the
dark at room temperature. Before the experiment, absorbance
of the ABTS∙+ solution was adjusted to 1.2 at 405 nm. Test
compounds were incubated with the ABTS∙+ solution for 30
minutes at RT. Assayswere done in 96-well plates in triplicate.
Absorbance was measured with Victor V3 multilabel reader
(405 nm). Antioxidant activity was expressed as the percent-
age of control (DMSO-treated) samples and was compared to
the effect of 12 𝜇M Trolox.
2.11. Cupric Ion Reducing Antioxidant Capacity (CUPRAC)
Assay. Measurement of the antioxidant capacity of EODB
was performed as described by Apak et al. [33], with the
followingmodifications: 12𝜇Mof Trolox was used as positive
control, final volumewas reduced to 100𝜇L, and themeasure-
ment was performed in 96-well microplates.
2.12. H
2
O
2
Scavenging Activity. Hydrogen-peroxide scaveng-
ing capacity was measured using the Ampliflu Red reagent
(10-acetyl-3,7-dihydroxyphenoxazine) in a cell-free system.
12 𝜇M EODB or 10 𝜇M ascorbic acid was incubated with
0.1 𝜇MH
2
O
2
(Sigma-Aldrich), 50𝜇M Ampliflu Red reagent,
and 0.1 U/mL horseradish peroxidase in phosphate buffered
saline for 5 minutes at room temperature. H
2
O
2
, in the
presence of horseradish peroxidase, reacts stoichiometrically
with Ampliflu Red reagent to generate the red-fluorescent
oxidation product, resorufin. Fluorescence was read with
excitation at 530 nm and emission at 590 nm using a Fluo-
roskan Ascent FL plate reader (Labsystems, Vantaa, Finland).
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2.13. Superoxide Scavenging Activity. Superoxide scavenging
capacity was measured with the NBT (nitroblue tetrazolium
chloride) reduction test as described [34] with modifica-
tions as follows. Superoxide was produced by the xan-
thine/xanthine oxidase system and NBT reagent (50 𝜇M
final concentration) was used to detect superoxide. NBT is
reduced to the blue NBT diformazan product by superoxide
[34]. 12 𝜇M EODB or 100 𝜇M ascorbic acid (positive con-
trol) was incubated with xanthine oxidase (0.1 U/mL) and
xanthine (50 𝜇M), in potassium phosphate buffered saline
(0.067M, pH7.8, supplemented with 0.7mg/mL BSA to keep
the produced NBT diformazan in solution and with 0.5mM
EDTA to chelate transition metals) in 200𝜇L final volume
for 2 minutes at room temperature. As a vehicle control,
DMSO was applied in the concentration present in the
EODB samples. The xanthine/xanthine oxidase reaction was
also run in the presence of 500U/mL superoxide dismutase
(SOD) and SOD-inhibitable NBT reduction was considered
to be due to superoxide production. Absorbance of NBT
diformazan was measured at 540 nm using a Multiskan MS
plate reader (Labsystems, Vantaa, Finland).
2.14. Western Blotting. Cells (3 × 106/sample) were washed
once in PBS and collected by scraping into 200𝜇L of
ice-cold lysis buffer (62.5mM Tris-HCl, pH 6.8, 2% SDS,
10% glycerol, 50mM DTT, 1mM PMSF, 1mM NaF, 1mM
Na
3
VO
4
, and protease inhibitors). The extracts were further
lysed with sonication, and the supernatant was collected after
centrifugation. Protein concentrations were determined with
the BCA reagent (Thermo Scientific). Proteins (30𝜇g/well)
were separated in 10% SDS-PAGE and transferred to nitro-
cellulose membranes. Membranes were blocked with 5%
BSA in Tris-buffered saline (TBS) for 1 hour. Primary anti-
bodies against JNK/stress-activated protein kinase, phospho-
JNK/stress-activated protein kinase (Thr183/Tyr185) (cell sig-
naling technology), were applied overnight at 4∘C. After
three washes in TBS containing 0.05% Tween 20, secondary
antibodies (peroxidase-conjugated goat anti-rabbit IgG, cell
signaling technology) were applied for 1 h. Blots were washed
three times in TBS containing 0.05% Tween 20 and once
in TBS, incubated in enhanced chemiluminescence reagent
(SuperSignal Chemiluminescent Substrate, Pierce). Bands
were evaluated by densitometry using ImageJ software.
2.15. Statistical Analysis. All experiments were performed
three times on different days. Analysis of variance was
performed by one way ANOVA followed by Tukey’s test for
statistical analysis and for the determination of significance
with 𝑃 < 0.05 considered as significant.
3. Results and Discussion
3.1. Results
3.1.1. Screening for Cardioprotective Compounds Protecting
from Doxorubicin Toxicity. We have screened the Chem-
Bridge DIVERset compound library consisting of 9680 com-
pounds. For this we used H9C2 rat cardiomyocytes and
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Figure 1: Screening for cardioprotective compounds. H9C2 cells
were treated with test compounds (10 𝜇M) for 30min followed by
a 24 h exposure to DOX (300 ng/mL). Viability was determined
with the MTT assay. Percent cytoprotection is plotted so that only
the most effective 15 compounds showing higher than 20% of
cytoprotective effects appear as “hits.” (SD values are not shown due
to the 3D presentation of data).
determined cell viability 24 h after doxorubicin treatment
(Figure 1). Compounds showing at least 20% cardioprotec-
tion were considered potentially cardioprotective. Fifteen
compounds met these criteria and were used in subsequent
experiments. According to our experience a drawback of
MTT-based or similar dehydrogenase activity-based viability
assays is the frequent occurrence of false positive hits.
Therefore we have analyzed the morphology of cells after
DOX treatment and retested the 15 primary hit compounds
(Figures 2(a) and 2(b)). By determining the surface area
occupied by living cells we have detected decreased via-
bility in DOX-treated samples. Out of the 15 compounds
retested only compound#10 appeared to convincingly exert
protective effect in DOX-treatedH9C2 cells (Figures 2(a) and
2(b)). This compound is 3-[2-(4-ethylphenyl)-2-oxoethyl]-
1,2-dimethyl-1H-3,1-benzimidazol-3-ium bromide (EODB)
(Figure 2(c)).
3.1.2. EODB Protects H9C2 Cells Both from Apoptotic and
from Necrotic Cell Death. We have further characterized the
cytoprotective effect of EODB. First we aimed to find the
optimal EODB concentration for the follow-up experiments.
Thereforewe pretreatedH9C2 cultureswith different concen-
trations of EODB and then treated the cells with DOX. Cell
cultures were stained with Coomassie dye and visual evalua-
tion suggested 12 𝜇M to be sufficient to providemaximal pro-
tection while at higher concentrations (especially at 100𝜇M)
toxicity could be observed (Figure S1 in SupplementaryMate-
rials available online at http://dx.doi.org/10.1155/2015/178513).
Thus we chose 12 𝜇M for the follow-up experiments. Next we
have confirmed the cytoprotective effect of EODB in another
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Figure 2: Reassessment of cardiocytoprotective effect of hit compoundswith amicroscopy-basedmethod.H9C2 cells were treatedwith the hit
compounds (12𝜇M) for 30min followed by a 24 h exposure to DOX (300 ng/mL). Cells were stained with Coomassie dye and photographed
with a Leica MC120 HD camera connected to a Leica DM IL LEDmicroscope (5x magnification) (a). Cell-covered area was determined with
the Tscratch software (b). Mean ± SEM of 3 independent experiments was calculated (b). Only compound#10 had significant (#𝑝 < 0.05)
cytoprotective effect in this assay. The structural formula of compound#10 (EODB) is shown on panel (c).
assay based on calcein-AM hydrolysis which confirmed its
significant cytoprotective effect against DOX-induced toxi-
city (Figure 3(a)). Doxorubicin-induced cell death has both
apoptotic and necrotic features [35, 36]. We have determined
cellular caspases-3 activity and release of LDL to assess
apoptotic and necrotic cell death, respectively (Figures 3(b)
and 3(c)). Pretreatment of the cells with EODB inhibited both
caspase-3 activation and LDH release indicating protection
from both apoptotic and necrotic cell death.
3.1.3. EODB Protects Primary Rat Cardiomyocytes from DOX-
Induced Damage. Cell-based screening programs typically
utilize immortalized cell lines due to relatively cheap culture,
easy manipulation (e.g., gene silencing), and availability of
high number of cells. However, the spontaneous or induced
mutations that were required for immortalization may alter
the biological behavior and responses of these cells.Therefore
we have also investigated the effect of EODB on primary
rat cardiomyocytes. We found that at 12 𝜇M concentration
EODB provided a significant protection from DOX-induced
toxicity both in MTT assay (Figure 4(a)) and in the calcein-
AM assay (Figure 4(b)). Furthermore, EODB also exerted
a significant inhibitory effect on DOX-induced caspase-3
activation (Figure 4(c)). Calcein assay data (Figure 4(b)) also
indicated some inherent toxicity of EODB because at 25𝜇M
concentration the cytoprotective effect of the compound
vanished.
3.1.4. EODB Lacks Antioxidant Activity but Inhibits JNK Acti-
vation. Since generation of ROS and RNS is considered as an
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Figure 3: Characterization of themode of DOX-induced cell death. H9C2 cells were pretreated (30min) with compound#10 and then treated
with DOX (300 ng/mL). After 24 h viability, apoptotic and necrotic cell deaths have been assessed with calcein-AM assay (a), caspase activity
(b), and lactate dehydrogenase (LDH) release (c), respectively. The lead compound significantly reduced DOX-induced cytotoxicity with a
stronger effect on necrosis than on the apoptotic cell death. Mean ± SEM of 3 independent experiments is presented. Stars indicate significant
(∗𝑝 < 0.05) DOX-induced cell death compared to control whereas hatch marks indicate significant (#𝑝 < 0.05) cytoprotection by the lead
compound.
important event in DOX-induced cardiac damage [37] and
many experimental compounds providing protection against
DOX-induced cardiotoxicity possess antioxidant effect [38]
we set out to determine whether or not EODB can scavenge
radicals. First we tested the compound in parallel with Trolox
(positive control) in ABTS decolorization assay (Figure 5(a))
but it had no radical scavenging effect. In the CUPRAC
assay which detects reducing activity, the compound also
showed no such effect (Figure 5(b)). Moreover, we have
also investigated whether EODB may neutralize H
2
O
2
or
superoxide. While the positive control vitamin C efficiently
inhibited H
2
O
2
-induced oxidation of the fluorescent target
molecule and also scavenged superoxide, EODB only had a
marginal (although statistically significant) inhibitory effect
on H
2
O
2
(Figure 5(c)) while it did not scavenge superoxide
(Figure 5(d)). Thus it appears that the cytoprotective effect of
EODB is not likely to be due to its antioxidant effect.
We have also investigated the potential role of two
prodeath MAP kinases p38 and JNK in the cytoprotective
effect of EODB. While p38 did not seem to be involved in
the mechanism (data not shown) JNKwas activated in DOX-
treatedH9C2 cells and EODB suppressedDOX-induced JNK
activation (Figure 5(d)).
3.1.5. EODB Does Not Interfere with the Antitumor Effect of
Doxorubicin. For a potential drug candidate to be used to
protect cardiomyocytes in DOX-treated cancer patients, it is
important not to compromise the antitumor effect of DOX.
DOX is used in the treatment of different kinds of tumors
including cancers of lung [39] and bone origin [40] as well
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Figure 4: EODBprotects primary rat cardiomyocytes fromDOX-induced injury. Rat primary cardiomyocyteswere pretreated for 30minwith
12𝜇M EODB or 20 𝜇M FeTPPs (positive control) followed by a 24 h exposure to DOX (300 ng/mL). Viability was assessed with MTT assay
(a) and calcein-AM assay (b) and data were expressed as percent cytoprotection. Caspase activity was determined as a marker of apoptosis
(c). Mean ± SEM of 3 independent experiments is presented. EODB provided significant (∗𝑝 < 0,05) protection as compared to vehicle in all
three assays.
as in different forms of leukemias [41]. Therefore we tested
whether or not EODB affects the cytotoxic effect of DOX in
A549 lung epithelial carcinoma cells, SAOS-2 osteosarcoma
cells, and in monocytic and T cell leukemia cell lines (THP-
1 and Jurkat, resp.). We found that EODB did not interfere
with the tumor cell killing activity of doxorubicin (Figure 6).
Interestingly, EODB alone (without DOX) was toxic to all
these cancer cell lines (Figures 6(a), 6(b), 6(e), and 6(f)), an
effect we have not observed in H9C2 cell cultures. EODB
also strongly inhibited the proliferation of A549 cells whereas
its antiproliferative effect on SAOS-2 cells was less marked
(Figures 6(c) and 6(d)). Analysis of Coomassie-stained A549
and SAOS-2 cultures also confirmed the toxic effect of EODB
on these tumor cell lines (Figure S2).
3.2. Discussion. HTS screens are typically applied on poten-
tial pharmacological targets implicated in the pathomech-
anism of diseases affecting large populations. Accordingly,
to our best of knowledge, HTS has not yet been used to
identify molecules protecting cardiomyocytes from DOX.
In our current study we aimed at proving the viability of
the HTS approach for the development of pharmacological
agents protecting cardiac cells from DOX-induced toxicity.
To this end we screened a small but diverse compound
library for cardioprotective effect and our viability-based
screen identified several hit compounds. However, keeping
in mind that methodological issues often render it difficult
to draw objective conclusions from cytoprotective assays
especially in the case of DOX-induced cardiotoxicity [42],
the hit compounds were retested in a different assay based on
morphological criteria (measurement of cell-covered surface
area). Only one of the test compounds (EODB) passed this
double test and in subsequent experiments we characterized
the protective effect of EODB. The most likely reason for
the discrepancy between the primary screening and the
retesting is that most hit compounds probably perturbed
8 Oxidative Medicine and Cellular Longevity
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the MTT assay leading to false positive results. EODB also
protected primary cardiomyocytes from DOX-induced cell
death suggesting that our findings may translate well to
preclinically more relevant conditions.
So far most experimental compounds that sufficiently
protected the heart or cardiomyocytes from DOX-toxicity
targeted reactive oxygen or nitrogen species. For example, a
vitamin E prodrug [23], flavonoids [43, 44], a peroxynitrite
decomposition catalyst ferroporphyrin compound [18], and
many other antioxidants proved effective in providing protec-
tion fromDOX-induced cardiac injury [45]. EODB, however,
is not likely to neutralize ROS or RNS species directly. It
did not scavenge ABTS or superoxide radicals nor did it test
positively in the CUPRAC antioxidant assay and its H
2
O
2
scavenging activity was not very prominent either. Thus it
is quite likely that the cardiocytoprotective effect of EODB
is indirect and may interfere with damage-signaling path-
ways. In the DOX-induced cardiotoxicity model, the lack of
antioxidant effect is not incompatible with cardioprotection
as indicated by the protective effect of inhibitors of poly(ADP-
ribosyl)ation [20], topoisomerase [46], or angiotensin type
1 receptor [47]. EODB may also target a step in one of the
many cell death pathways. Our data demonstrated that it
inhibits both apoptotic and necrotic cell deaths suggesting
that it more likely interferes with a proximal event of damage-
signaling rather than specifically targeting one particular cell
death pathway. In fact such “indirect” effects may bear higher
clinical relevance than direct radical scavenging, because,
despite promising preclinical data, antioxidant approaches
(e.g., N-acetyl cysteine or iron chelation) were not effective
in humans [48, 49]. Cell death promoting MAP kinases may
represent ideal targets for cytoprotective approaches [50–
52]. Under our assay conditions JNK but not p38 kinase
was activated in DOX-treated cells and EODB efficiently
inhibited DOX-induced JNK phosphorylation. Whether this
represents a direct effect of the compound on the kinase or it
inhibits an upstream event in the signaling cascade requires
further investigation.
Structural analysis of EODBmay also give hints to explain
both the protective effect of the compound and its side
effects. EODB contains a benzimidazole moiety which may
be linked to some of these effects. Benzimidazole deriva-
tives represent a pharmacologically active family of agents
with demonstrated antiviral [53, 54], antimicrobial [55, 56],
and antidiabetic effects [57]. Furthermore, telmisartan, an
angiotensin II receptor blocker, contains two benzimidazole
moieties. Interestingly, in a rat model, telmisartan has been
shown to limit the cardiotoxic effect of DOX as verified
by improved hemodynamic status, suppressed expression
of matrix metalloproteinase activity p22(phox), p47(phox),
p67(phox), nuclear factor kappa B, and Nox4, and reduced
oxidative DNA damage, lipid peroxidation, and cell death
[47, 58]. It is tempting to speculate that EODB may also
possess angiotensin II receptor blocking effect which might
be the key factor underlying its cardiocytoprotective effect.
Moreover, compounds with a benzimidazole scaffold also
have demonstrated antitumor effect via inhibition of topoi-
somerases [59–61]. On the one hand this may be important
for explaining both theDOX-protective effect (see above) and
the toxic effect of EODB on tumor cell lines. EODB did not
interfere with the antitumor effect of DOX in the four tumor
cell lines tested. In fact, it also proved cytotoxic in the absence
of DOX.We have not observed toxicity onH9C2 cells (only at
100 𝜇M) but in primary rat cardiomyocytes the toxicity may
have contributed to the limited though significant protective
effect of EODB.
In summary, our experiments proved the viability of
the cell-based HTS approach for the identification of DOX
protective compounds. EODB protected both H9C2 cells
and rat primary cardiomyocytes from DOX-induced toxicity
without hampering the antitumor effect of DOX. Through
structure optimization EODB may serve as a template for
the development of compounds protecting heart cells from
DOX-induced toxicity. Further investigations are needed to
identify the exact molecular target of this promising drug
candidate.
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